3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
12
Sarcoma, Kaposi
5
HIV Infections
5
Acquired Immunodeficiency Syndrome
5
Myeloproliferative Disorders
4
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Leukemia, Monocytic, Acute
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Advanced Cancer
1
Interventions
Fulvestrant
6
Letrozole
4
exemestane
3
dalpiciclib
3
Trastuzumab
3
Docetaxel
3
Capecitabine
3
Anastrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
apatinib
2
Irinotecan
2
Gemcitabine
2
tusamitamab ravtansine
1
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
nirogacestat
1
margetuximab
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Tamoxifen
1
Rogaratinib
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Breast Cancer Metastatic
×
Liposomes
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled